PDT Partners’s Heron Therapeutics HRTX Stock Holding History

PDT Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-167,749	Closed	-$419K	–	640
2022 Q4	$419K	Sell	167,749 -136,710	-45%	-$440K	0.07%	421
2022 Q3	$1.28M	Sell	304,459 -65,475	-18%	-$256K	0.19%	153
2022 Q2	$1.03M	Sell	369,934 -129,897	-26%	-$522K	0.09%	384
2022 Q1	$2.86M	Buy	499,831 +436,461	+689%	+$3.19M	0.25%	107
2021 Q4	$579K	Buy	+63,370	New	+$647K	0.04%	492
2021 Q2	–	Sell	-36,028	Closed	-$584K	–	875
2021 Q1	$584K	Buy	+36,028	New	+$642K	0.04%	478

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

PDT Partners's HRTX Position: Q1 2023 in Review

PDT Partners sold out of Heron Therapeutics (HRTX) in Q1 2023, closing a stake of 167,749 shares — an estimated $419K sold.

PDT Partners first reported a position in HRTX in Q1 2021 and held it in 6 quarters. The position peaked at $2.86M in Q1 2022. 162 funds tracked by Wall St. Rank hold HRTX as of Q1 2023.

PDT Partners reported no remaining Heron Therapeutics position as of Q1 2023 after selling out during the quarter.
PDT Partners sold 167,749 Heron Therapeutics shares in Q1 2023, an estimated $419K.
PDT Partners first reported a position in Heron Therapeutics in Q1 2021 and held it in 6 quarters.
PDT Partners's Heron Therapeutics position peaked at $2.86M in Q1 2022.
162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.